Neurotech Pharmaceuticals' eye cell therapy implant faces a setback with the FDA extending its review deadline to 18 March 2025. The NT-501 implant aims to treat MacTel, a rare eye disease. The implant contains RPE cells releasing therapeutic proteins for continuous treatment.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing